elezanumab

Home
Ligands
elezanumab

GtoPdb Ligand ID: 9290

Synonyms: ABT-555 | AE12-1Y-QL

Comment: Elezanumab (ABT-555) is a fully human monoclonal antibody targeting repulsive guidance molecule-a (RGMA), in development as a potential therapy for multiple sclerosis (MS).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2013112922 [2].

No information available.

No information available.

Summary of Clinical Use
Elezanumab (ABT-555) is being evaluated in Phase 1 clinical trial in patients with relapsing forms of MS (see NCT02601885).

Summary of Clinical Use

Elezanumab (ABT-555) is being evaluated in Phase 1 clinical trial in patients with relapsing forms of MS (see NCT02601885).

Mechanism Of Action and Pharmacodynamic Effects
Inhibition of RGMA is expected to promote regeneration and neuroprotection in MS [1], acting to concurrently block autoimmune demyelination and axon injury.

Mechanism Of Action and Pharmacodynamic Effects

Inhibition of RGMA is expected to promote regeneration and neuroprotection in MS [1], acting to concurrently block autoimmune demyelination and axon injury.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02601885	A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis	Phase 1 Interventional	AbbVie